Medicine and Dentistry
Acute Kidney Injury
20%
Angiotensin Converting Enzyme 2
20%
Anticoagulation
28%
Antithrombotic
26%
Apheresis
28%
Apixaban
82%
Aptamer
20%
Biological Therapy
20%
Bleeding
44%
Blood Clotting Factor 10a Inhibitor
42%
Blood Culture
20%
Blood Stasis
56%
Blood Transfusion
64%
Coronavirinae
24%
COVID-19
86%
Direct Oral Anticoagulant
25%
Diseases
26%
End Stage Renal Disease
20%
Erythrocyte Transfusion
20%
Fibrinogen Concentrate
19%
Health System
20%
Heart Surgery
46%
Hemoglobin Determination
20%
Host Cell
20%
Hypochromic Anemia
20%
Hysterectomy
20%
Infection
25%
Major Bleeding
47%
Mixing Study
20%
Partial Thromboplastin Time
16%
Pathologist
40%
Persistent Truncus Arteriosus
13%
Placenta Accreta
20%
Plasma Exchange
20%
Platelet
39%
Prothrombin Complex
40%
Randomized Controlled Trial
20%
Receptor Binding
32%
Renal Replacement Therapy
20%
Rivaroxaban
62%
Severe Acute Respiratory Syndrome Coronavirus 2
36%
Sulfhemoglobinemia
20%
Thrombocyte Transfusion
13%
Thromboembolism
15%
Thrombophilia
20%
Thrombosis
53%
Ticagrelor
20%
Transfusion Medicine
40%
Venous Thromboembolism
23%
Von Willebrand Factor
40%
Keyphrases
Academic Health System
20%
Acid-base Homeostasis
20%
Acute Kidney Injury
20%
Andexanet Alfa
20%
Anti-Xa
20%
Anti-Xa Level
22%
Apheresis Procedures
20%
Apixaban
43%
Bamlanivimab
20%
Carboxyhemoglobinemia
20%
Casirivimab-imdevimab
13%
Clinical Transfusion Medicine
20%
College of American Pathologists
20%
Complex Cardiac Surgery
20%
Convalescent Plasma
20%
CoV-2
20%
CyaB
20%
Direct Oral
20%
DOAC Levels
11%
End-stage Renal Disease
20%
Etesevimab
10%
External Quality Assessment
20%
Factor Concentrates
20%
Factor Xa Inhibitors
22%
Fibrinogen Concentrate
14%
Gp120
20%
Hemostasis
27%
Hemostasis Laboratory
20%
Hospitalized Patients
43%
Inlet Flow Rate
10%
Level Monitoring
20%
Major Bleeding
21%
Massive Blood Transfusion
20%
Package Labels
12%
Parenteral Anticoagulants
24%
Peripheral Blood Stem Cell Collection
10%
Peripheral Venous Access
40%
Proficiency Testing
20%
Removal Time
20%
Renal Replacement Therapy
20%
Rivaroxaban
23%
SARS-CoV-2 Spike Protein
20%
Selected Topic
20%
Therapeutic Apheresis
40%
Thrombosis
27%
Total Processing Time
20%
Tracking System
20%
Ultrasound-based
20%
Venous Thromboembolism
20%
Von Willebrand Factor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acetylsalicylic Acid
10%
Acute Kidney Failure
20%
Adenylate Cyclase
20%
Amphotericin B Deoxycholate
6%
Andexanet Alfa
20%
Angiotensin Converting Enzyme 2
20%
Anticoagulant Agent
6%
Antimalarial Agent
6%
Antimicrobial Agent
6%
Antiplatelet
9%
Apixaban
100%
Aptamer
20%
Bleeding
45%
Blood Clotting Factor 10a Inhibitor
24%
Blood Stasis
11%
Cohort Study
22%
Comorbidity
5%
Coronavirinae
65%
Direct Oral Anticoagulant
25%
Diseases
71%
Dose-Response Study
10%
Drug Concentration
5%
End Stage Renal Disease
20%
Fibrinogen Concentrate
14%
Infection
40%
Inflammation
6%
Leukocytosis
6%
Monoclonal Antibody
20%
Mortality Rate
16%
Neutropenia
20%
Neutrophilia
20%
Placenta Accreta
20%
Plasmodium falciparum
20%
Population Study
5%
Prothrombin
12%
Randomized Clinical Trial
20%
Receptor
20%
Replacement Therapy
20%
Retrospective Study
6%
Rivaroxaban
80%
SARS Coronavirus
21%
Sepsis
6%
Thromboembolism
10%
Thromboplastin
16%
Thrombosis
34%
Ticagrelor
20%
Venous Thromboembolism
23%
Virus Infection
5%
Vitronectin
5%